Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor Marc-Antoine Benderra, MD, Sandrine Aspeslagh, PhD, Sophie Postel-Vinay, PhD, Ludovic Bigot, MD, Thierry De Baere, PhD, Yohann Loriot, PhD, Ludovic Lacroix, PhD, Christophe Massard, PhD, Gilles Vassal, PhD, Fabrice Andre, PhD, Jean-Charles Soria, PhD* DITEP (Departement d’Innovations Therapeutiques et Essais Precoces), Gustave Roussy Cancer Campus, Villejuif, France Faculte de medicine Paris-Sud XI, Kremlin-Bicetre, France U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France Radiologie interventionnelle, Gustave Roussy Cancer Campus, Villejuif, France Departement de Medecine Oncologique, Gustave Roussy Cancer Campus, Villejuif, France Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France Departement de Biologie et Pathologie Medicales, Gustave Roussy Cancer Campus, Villejuif, France Direction de la recherche clinique, Gustave Roussy Cancer Campus, Villejuif, France